Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Jul 17, 2007
A pure pharmaceutical play and he cautious on this sector. Concerned about lawsuits, patent litigations on generic drugs and also patent expiries.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$25.96

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 21, 2007
The model price is $42, a 63% positive differential. All the drug companies are moving, except this one. Huge cash flows. 5% dividend yield.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.92

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 07, 2007
47% positive differential. The most mispriced in the Dow Jones. bonus of 5% dividend yield. They are in around $26.63.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.29

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 24, 2007
(A Top Pick July 21/06. Up 14.5%.) 5% yield. His model price is $48.51, a 52% positive differential. The cheapest stock in the Dow Jones.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$27.28

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

May 16, 2007
Is preforming quite well without a lot of fanfare. Thinks it is going to trade to a discount, would rather go to a Sheering or Abbot.
Photo of David BurrowsDavid BurrowsUnlock Rating
$27.32

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 02, 2007
Hasn't moved but has the most value of similar stocks. Massively mispriced.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

May 01, 2007
Blue chip. Nice dividend. Don't expect too much excitement.
Photo of Michael SmedleyMichael SmedleyUnlock Rating
$26.59

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 01, 2007
(A Top Pick May 9/06. Up 4.2%.) Yield gave him another 4%. Sold their consumers products division for $19 billion so have a huge amount of cash on the books. Can't see a lot of downside here.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 26, 2007
Has value characteristics which is positive, but he can't get comfortable with their largest drug Lipidor going off patent in 2011. Does not all they'll make up for this.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$26.72

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 16, 2007
His value drug play. Growth drug play is Teva Pharmaceutical (TEVA-Q). Pharmaceuticals got the wind kicked out of them a couple of years ago and are now showing some rebound. Very nice yield. Huge cash hoard and are buying back stock and probably will increase dividends again.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.94

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Apr 16, 2007
Looks like it is in the process of breaking the downtrend. That was established with the recent higher lows. If you own, he would Hold.
Photo of John ManleyJohn ManleyUnlock Rating
$26.94

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2007
(A Top Pick May 10/06. Up 5.3%.) One of the cheapest stocks on the S&P500. His model price is $40.47 giving it a 55% positive differential. Any positive catalyst will help the stock price. Dividends are almost 5%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.46

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 28, 2007
The drug stocks in the US have been beat up. The problems they had have gotten somewhat better. Increased their dividend and are investing in more R&D. Buying back shares. Low multiple.
Photo of Norman LevineNorman LevineUnlock Rating
$25.18

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 22, 2007
Doesn't like many of the big pharmaceuticals. Has a great deal of revenue at risk with Lipitor coming off patent and they don't have a lot to replace it.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.79

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 13, 2007
(A Top Pick Dec 5/06. Up to .3%.) Still has lots of upside and it has a good yield. Have a lot of cash.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.94

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 571 to 585 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.89$313.23
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like